Company profile for YolTech Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

YolTech Therapeutics, a biotech company, specializes in integrating mRNA and gene editing technology to advance next-generation mRNA drugs and in vivo gene editing drugs. As a pre-clinical stage gene editing biotech, YolTech has established a leading genome editing platform and mRNA-LNP library, showcasing proficiency in the discovery of novel Cas and base editors. With robust production capabilities for LNP drug manufacturing...
YolTech Therapeutics, a biotech company, specializes in integrating mRNA and gene editing technology to advance next-generation mRNA drugs and in vivo gene editing drugs. As a pre-clinical stage gene editing biotech, YolTech has established a leading genome editing platform and mRNA-LNP library, showcasing proficiency in the discovery of novel Cas and base editors. With robust production capabilities for LNP drug manufacturing and global IP protection, the company has developed a pipeline featuring 10 genetic medicines concentrated on cardiovascular diseases, infectious diseases, and rare diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
No. 58 Tanzhu Road, Minhang District, Shanghai
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/yoltech-therapeutics-raises-45-million-in-series-b-financing-led-by-astrazeneca-cicc-302553734.html

PR NEWSWIRE
11 Sep 2025

https://www.prnewswire.com/news-releases/yoltech-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-yolt-101-an-in-vivo-base-editing-therapy-to-treat-heterozygous-familial-hypercholesterolemia-hefh-302475072.html

PR NEWSWIRE
05 Jun 2025

https://www.prnewswire.com/news-releases/yoltech-announces-first-clinical-data-from-ongoing-investigator-initiated-trial-of-yolt-101-an-in-vivo-base-editing-therapy-for-familial-hypercholesterolemia-302439382.html

PR NEWSWIRE
28 Apr 2025

https://www.prnewswire.com/news-releases/yoltech-therapeutics-announces-positive-clinical-data-for-yolt-203-an-in-vivo-gene-editing-therapy-for-primary-hyperoxaluria-type-1-ph1-302384408.html

PR NEWSWIRE
25 Feb 2025

https://www.prnewswire.com/news-releases/yoltech-therapeutics-to-initiate-a-clinical-trial-for-yolt-204-a-first-in-class-bone-marrow-targeted-in-vivo-gene-editing-therapy-for--thalassemia-302355739.html

PR NEWSWIRE
22 Jan 2025

https://www.prnewswire.com/news-releases/yoltech-therapeutics-announces-successful-completion-of-dose-escalation-phase-in-phase-i-trial-of-yolt-201-for-attr-302337849.html

PR NEWSWIRE
21 Dec 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty